HCC CONNECT

❌ Results from IMbrave050 do not support atezolizumab + bevacizumab as an adjuvant therapy for all high-risk HCC. Initial RFS benefit with atezolizumab + bevacizumab versus active surveillance was not sustained. ✅ Safety profile of atezolizumab + bevacizumab remained manageable and consistent with each agent and underlying HCC. Do you know the key HCC data from ESMO 2024? Find out in the video update by Dr Richard Finn here, including key takeaways from HIMALAYA, CheckMate 9DW & LEAP-012👇 https://ow.ly/6pe250TKmIv #MedEd #HCC #IO

🚨 Abstracts for the ILCA Annual Conference have been released! We've made a list of some that we're looking forward to, look them up below: https://ow.ly/UN8Z50TKvTG 🗓️ 17th - 19th October, 2024 📍 Toronto, Canada Follow HCC CONNECT for more updates & check out our medical education👇 https://ow.ly/sgAb50TKvTK #MedEd #HCC #ILCA24 International Liver Cancer Association (ILCA)

✅ Results from LEAP-012 suggest that lenvatinib + pembrolizumab + transarterial chemoembolization may be accepted as a new standard of care in intermediate HCC. 📈 The combination showed a statistically significant and clinically meaningful improvement in progression free survival versus double placebo + TACE. The adverse event profile was consistent with known safety profiles of lenvatinib, pembrolizumab, and TACE. Do you know the key HCC data from ESMO 2024? Find out in the video update by Dr Richard Finn here👇 https://ow.ly/SWO750TKw53 #MedEd #HCC #IO

❗Have you watched our video update from ESMO 2024? Dr Richard Finn reviews the data from HIMALAYA, CheckMate 9DW, LEAP-012 & IMbrave050 & discuss the key takeaways: ➡️ Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Rimassa L, et al. (Abstract 947MO, ESMO2024) ➡️ Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW Decaens T, et al. (Abstract 965MO, ESMO 2024) ➡️ Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study. Llovet J, et al. (Abstract LBA3, ESMO 2024) ➡️ Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) (Abstract LBA39, ESMO 2024) Yopp A, et al. Watch the short video update and download the accompanying slides👇 https://ow.ly/qqBA50TFvNY #MedEd #HCC #ESMO24

⚠️ As part of Liver Cancer Awareness Month, Global Liver Institute is running weekly conversations with experts. "Let's Create Equitable Care in Liver Cancer", with Andrea Reid, MD, MPH 🗓️ Wednesday, October 9 ⏰ 12:00 pm ET Find out more information👇 https://ow.ly/Gwar50TGG0G #MedEd #HCC #LiverCancerAwarenessMonth

📢 Don't miss the Digestive Cancers Europe webinar for Liver Cancer Awareness Month. Titled "It is Never Too Early to Act", the agenda includes an update in screening and early diagnosis, ideas on how we can improve the situation and highlights from the HCC Prevention & Diagnosis research project. 🗓️ October 24th ⏰ 10:00 - 11:00 CET Find out more information👇 https://ow.ly/EYpu50TwZqB #MedEd #HCC #LiverCancerAwarenessMonth

💡 Results from CheckMate 9DW further support nivolumab + ipilimumab as a potential first-line treatment option for patients with unresectable HCC. Nivolumab + ipilimumab demonstrated statistically significant overall survival benefit versus lenvatinib or sorafenib, with higher objective response rate and durable responses, in patients with previously untreated unresectable HCC ✅ Safety was manageable and consistent with the established safety profile of the regimen. Do you know the key HCC data from ESMO 2024? Find out in the video update by Dr Richard Finn here👇 https://ow.ly/1VST50TB7iW #MedEd #HCC #IO

🎉 October is liver cancer awareness month! Make sure to follow us to keep up to date with resources, webinars and other events and join us to help improve education around HCC. Check out our independent medical education resources👇 https://ow.ly/eA6T50TB7TA #MedEd #HCC #LiverCancerAwarenessMonth

🚨 The first Global Liver Institute #OctoberIs4Livers Health Equity Roundtable is on October 3rd at 1pm ET! Focusing on advancing prevention, treatment and care, the discussion will include a policy briefing on liver cancer. Find out more information👇 https://ow.ly/Vmlz50Tyyet #MedEd #LiverCancerAwarenessMonth

✅ Results from the HIMALAYA study showed STRIDE (single tremelimumab regular interval durvalumab) demonstrated an unprecedented 5-year survival rate. There were no additional serious treatment-related adverse related events (TRAEs) in the extended follow up. Do you know how many patients were alive with STRIDE at 5 years? Watch the video update from Dr Richard Finn here👇 https://ow.ly/FaNz50TweLf #MedEd #HCC #IO